NCT00846976View on ClinicalTrials.gov

Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

December 31, 1994

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Bicalutamide

200mg daily

Trial Locations (1)

Unknown

Research Site, New York

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY